Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Overview

About this study

This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years and ≤ 80 years old.
  • High risk smoldering myeloma, which is untreated, as defined by presence of any two of the following:
    • Serum M spike > 2 gm/dL; OR
    • An involved to uninvolved FLC ratio > 20; OR
    • Bone marrow PC% > 20%.
  • Total score of 9 or above using the following scoring system:
    • FLC Ratio >10-25
      • Score:  2
    • FLC Ratio >25-40
      • Score:  3
    • FLC Ratio > 40
      • Score:  5
  • Serum M protein (g/dL)
    • > 1.5-3
      • Score: 3
    • > 3
      • Score:  4
  • BMPC%
    • >15-20
      • Score: 2
    • > 20-30
      • Score: 3
    • > 30-40
      • Score:  5
    • > 40
      • Score:  6
  • FiSH abnormality (t(4,14), t(14,16), 1q gain, or del13q
    • Score:  2
  • The following laboratory values obtained ≤ 14 days prior to registration:
    • Calculated creatinine clearance (using Cockcroft-Gault equation below)* ≥ 30 mL/min;
    • Absolute neutrophil count (ANC) ≥ 1000/mm³ (without the use of growth factors);
    • Platelet count  ≥ 75000/mm ³;
    • Hemoglobin ≥ 8.0 g/dL;
    • Total bilirubin ≤ 1.5 x ULN;
    • ALT and AST ≤ 3 x ULN;
  • *Cockcroft-Gault Equation:
    • Creatinine clearance for males = (140 - age)(actual body weight in kg)/ (72)(serum creatinine in mg/dL);
    • Creatinine clearance for females = (140 - age)(actual body weight in kg)(0.85)/(72)(serum creatinine in mg/dL).
  • LVEF ≥ 40%.
  • ECOG performance status (PS) 0 or 1.
  • Previously untreated.
  • Provide informed written consent.
  • Negative pregnancy test done ≤ 14 days prior to C1D1, for women of childbearing potential only.
  • All study participants must be registered into the mandatory Revlimid REMSR program and be willing and able to comply with the requirements of the REMSR program.
  • Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMSR program.
  • Willing to follow strict birth control measures as outlined in the protocol.  Female subjects: If they are of childbearing potential, agree to one of the following:
    • Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of trial drug; AND
    • Must also adhere to the guidelines of any treatmentspecific pregnancy prevention program, if applicable; OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).
  • Male subjects: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:
    • Agree to practice effective barrier contraception during the entire trial treatment period and through 90 days after the last dose of trial drug; OR
    • Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable; OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).
  • Willing to return to enrolling institution for follow-up during the Active Treatment Phase of the trial.
  • Male subjects must agree not to donate sperm for at least 90 days after the last dose of study treatment.
  • Willing to provide samples for planned research.
  • Life expectancy > 6 months.
  • Able to take aspirin (325 mg) daily as prophylactic anticoagulation. Subjects intolerant to aspirin may use warfarin, novel oral anticoagulants, or low dose molecular weight heparin.

Exclusion Criteria:

  • MGUS, standard risk smoldering myeloma, active myeloma by current IMWG definition, light chain amyloidosis with organ involvement or patients with extramedullary disease.
  • Diagnosed or treated for another malignancy ≤ 2 years before trial enrollment or previously diagnosed with another malignancy and have any evidence of residual disease.
    • NOTE: Subjects with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  • If any of the following exist at screening, subject will not be eligible for trial because this trial involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
    • Pregnant women;
    • Nursing women;
    • Men or women of childbearing potential who are unwilling to employ adequate contraception (per protocol).
  • Other co-morbidity which would interfere with subject's ability to participate in trial; e.g., uncontrolled infection, uncompensated heart or lung disease.
  • Other concurrent chemotherapy, or any ancillary therapy considered investigational.
    • NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment.
  • Peripheral neuropathy ≥ Grade 3 on clinical examination or grade 2 with pain within 30 days prior to C1D1.
  • Major surgery ≤ 14 days prior to C1D1.
  • Evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
    • Note: Prior to trial entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.
  • NYHA II, III, IV heart failure.
  • Known human immunodeficiency virus (HIV) positive.
  • Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.
    • EXCEPTION: subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
  • Known or suspected active hepatitis C infection.
  • Any medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol.
  • Prior radiation therapy for bony lesions or plasmacytomas
  • Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products. Known allergies, hypersensitivity, or intolerance to trial drugs.
  • Inability to comply with protocol/procedures.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shaji Kumar, M.D.

Open for enrollment

Contact information:

Katrina Croghan CCRP

(507) 538-1866

Croghan.Katrina@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20426331

Mayo Clinic Footer